Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-08-23FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for LETAIRIS (ambrisentan) by Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2019-08-13Clinical Trial Update: Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension [Phase 1, Phase 2]
A clinical trial investigating adipose-derived mesenchymal stem cells for pulmonary arterial hypertension across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2019-08-07Clinical Trial Update: Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients [Phase 2]
Phase 2 trial update on QCC374 in pulmonary arterial hypertension (terminated; results posted).
-
CLINICAL_TRIALS trial_result · 2019-07-22Clinical Trial Update: A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001) [Phase 1]
Phase 1 single-dose study of MK-8892 in healthy or PAH populations to assess safety, tolerability, PK and PD; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial) [Phase 2, Phase 3]
Clinical trial update for the SUPERIOR trial evaluating sildenafil for sustained pulmonary arterial hypertension after mitral valve surgery;…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-06-18Clinical Trial Update: Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan [Phase 3]
Phase 3 open-label trial update for QTI571 (selexipag? or QTI571) provided to PAH patients who participated in an extension study in Japan; …
-
FDA approval · 2019-06-10FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for OPSUMIT (macitentan) submitted by Actelion Pharmaceuticals US, Inc.
-
FDA approval · 2019-05-31FDA Approved: SILDENAFIL — Original Application (ANI Pharmaceuticals, Inc.)
FDA approves ANI Pharmaceuticals' sildenafil citrate as a generic drug under an original application.
-
CLINICAL_TRIALS trial_result · 2019-05-22Clinical Trial Update: Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension [Phase 2]
Phase 2 clinical trial assessing safety and efficacy of fluoxetine in pulmonary arterial hypertension has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-05-21Clinical Trial Update: Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension [Phase 3]
This is a Phase 3 safety study evaluating switching from oral selexipag to intravenous selexipag in patients with stable pulmonary arterial …
-
FDA approval · 2019-05-16FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) filed by Actelion Pharmaceuticals US, Inc., resulting in updated labeling.
-
FDA approval · 2019-05-16FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) from Actelion Pharmaceuticals US, Inc., marking an update to the drug's labe…
-
FDA approval · 2019-04-26FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for TRACLEER (bosentan) from Actelion Pharmaceuticals US, Inc., resulting in an updated labeling…
-
FDA approval · 2019-04-26FDA Approved: BOSENTAN — Original Application (Actavis Pharma, Inc.)
FDA approved a generic bosentan from Actavis Pharma under an original ANDA (ANDA207110). The approval covers its use for pulmonary arterial …
-
FDA approval · 2019-04-26FDA Approved: AMBRISENTAN — Original Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s original application for Ambrisentan as a generic version, for treatment of pulmonary arterial hypertension.
-
FDA approval · 2019-04-26FDA Approved: BOSENTAN — Original Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved Zydus Pharmaceuticals USA Inc.'s Original Application for bosentan, authorizing a generic bosentan product.
-
FDA approval · 2019-04-26FDA Approved: BOSENTAN — Original Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical Industries' original application for Bosentan, enabling a generic version of the endothelin receptor ant…
-
FDA approval · 2019-04-23FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approves a supplemental application for OPSUMIT (macitentan) from Actelion Pharmaceuticals US, Inc., related to the existing macitentan …
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome [Phase 3]
Phase 3 trial assessing long-term safety, tolerability, and efficacy of macitentan in Eisenmenger syndrome; study terminated with results po…
-
CLINICAL_TRIALS trial_result · 2019-04-10Clinical Trial Update: Selonsertib in Adults With Pulmonary Arterial Hypertension [Phase 2]
Phase 2 clinical trial update for Selonsertib in adults with Pulmonary Arterial Hypertension has completed enrollment with results posted.
-
FDA approval · 2019-04-10FDA Approved: AMBRISENTAN — Original Application (Sigmapharm Laboratories, LLC)
FDA approved a generic version of ambrisentan (original application) from Sigmapharm Laboratories for pulmonary arterial hypertension.
-
CLINICAL_TRIALS trial_result · 2019-04-08Clinical Trial Update: Crossover Study From Macitentan or Bosentan Over to Ambrisentan [Phase 4]
A phase 4 crossover study evaluating switching from macitentan or bosentan to ambrisentan in pulmonary arterial hypertension has been termin…
-
FDA approval · 2019-04-02FDA Approved: SILDENAFIL — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for sildenafil submitted by Torrent Pharmaceuticals Limited.
-
FDA approval · 2019-03-28FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for LETAIRIS (ambrisentan) filed by Gilead Sciences, expanding its labeling related to treatment of …
-
FDA approval · 2019-03-28FDA Approved: AMBRISENTAN — Original Application (Actavis Pharma, Inc.)
FDA approved the original application for ambrisentan (generic) submitted by Actavis Pharma, enabling the generic version to be marketed. Th…